Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: A comparative review

被引：30

作者：

Ranieri, Girolamo ^{[1
]}

Pantaleo, Marianna ^{[2
]}

Piccinno, Mariagrazia ^{[2
]}

Roncetti, Maria ^{[2
]}

Mutinati, Maddalena ^{[2
]}

Marech, Ilaria ^{[3
]}

Patruno, Rosa ^{[4
]}

Rizzo, Annalisa ^{[2
]}

Sciorsci, Raffaele Luigi ^{[2
]}

机构：

[1] Canc Inst Giovanni Paolo II, Natl Canc Res Ctr, Integrated Sect Transat Med Oncol, Intervent Radiol Unit, Bari, Italy

[2] Univ Bari Aldo Moro, DETO, Bari, Italy

[3] Univ Bari, Sch Med, Sect Internal Med & Clin Oncol, Dept Biomed Sci & Human Oncol, Bari, Italy

[4] ASL BAT, Dept Prevent & Anim Ealth, Barletta, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2013年 / 88卷 / 02期

关键词：

Tyrosine kinase receptors; Tyrosine kinase inhibitors; Angiogenesis; Breast cancer; Women; Pets; Comparative oncology; Bitch; Queen; ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; MAST-CELL TUMORS; GASTROINTESTINAL STROMAL TUMORS; TOCERANIB PHOSPHATE PALLADIA(TM); CHRONIC MYELOID-LEUKEMIA; PHASE-II; C-KIT; FACTOR-RECEPTOR; DOUBLE-BLIND;

D O I：

10.1016/j.critrevonc.2013.05.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tyrosine kinase receptors (TKRs) play a key role in tumour cell proliferation and survival since they are involved in endothelial cell activation leading to tumour neoangiogenesis. In particular, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-KitR), and colony-stimulating factor 1 (CSF-1) are overexpressed or constitutively activated in human and pet malignancies. A variety of small molecule inhibitors targeting specific tyrosine kinases (known as tyrosine kinase inhibitors or TKIs) have recently been approved, or are under investigation, for the treatment of human cancer. TKI application in animal cancer is however relatively recent. This review aims to illustrate the major aspects of tyrosine kinase dysfunctions, with special regard to human and animal cancer of the mammary gland, providing an update on the background of the anti-angiogenic and anti-neoplastic properties of TKIs in human and veterinary cancer. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：293 / 308

页数：16

共 50 条

[31] Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis [J].

Yu, Jiayi ;

Liu, Zheran ;

Su, Yonglin ;

Peng, Xingchen ;

Xie, Yuping .

CLINICAL ENDOCRINOLOGY, 2024, 100 (04) :379-388

[32] Synergistic Activity of an Antimetabolite Drug and Tyrosine Kinase Inhibitors against Breast Cancer Cells [J].

Wu, Yushan ;

Zhang, Dongxing ;

Wu, Baofan ;

Quan, Yuan ;

Liu, Dongwu ;

Li, Yanyan ;

Zhang, Xiuzhen .

CHEMICAL & PHARMACEUTICAL BULLETIN, 2017, 65 (08) :768-775

[33] HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now [J].

Schlam, Ilana ;

Swain, Sandra M. .

NPJ BREAST CANCER, 2021, 7 (01)

[34] The role of tyrosine kinase inhibitors in the treatment of HER2+metastatic breast cancer [J].

Le Du, Fanny ;

Dieras, Veronqiue ;

Curigliano, Giuseppe .

EUROPEAN JOURNAL OF CANCER, 2021, 154 :175-189

[35] Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer [J].

Felicetti, Francesco ;

Nervo, Alice ;

Piovesan, Alessandro ;

Berardelli, Rita ;

Marchisio, Filippo ;

Gallo, Marco ;

Arvat, Emanuela .

EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (12) :1093-1098

[36] Nursing Management and Adverse Events in Thyroid Cancer Treatments with Tyrosine Kinase Inhibitors. A Narrative Review [J].

De Leo, Aurora ;

Di Simone, Emanuele ;

Spano, Alessandro ;

Puliani, Giulia ;

Petrone, Fabrizio .

CANCERS, 2021, 13 (23)

[37] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: Current status and future development [J].

Normanno, N ;

De Luca, A ;

Maiello, MR ;

Mancino, M ;

D'Antonio, A ;

Macaluso, M ;

Caponigro, F ;

Giordano, A .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 :2611-2617

[38] Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity-a perspective overview [J].

Baglini, Emma ;

Chiaverini, Lorenzo ;

Tolbatov, Iogann ;

Taliani, Sabrina ;

Da Settimo, Federico ;

La Mendola, Diego ;

Barresi, Elisabetta ;

Marzo, Tiziano .

BIOMETALS, 2024, 37 (02) :275-288

[39] Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis [J].

Yu, Yushuai ;

Huang, Kaiyan ;

Lin, Yuxiang ;

Zhang, Jie ;

Song, Chuangui .

CANCER MEDICINE, 2023, 12 (14) :15090-15100

[40] Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer:: a review [J].

Schoffski, P. ;

Dumez, H. ;

Clement, P. ;

Hoeben, A. ;

Prenen, H. ;

Wolter, P. ;

Joniau, S. ;

Roskams, T. ;

Van Poppel, H. .

ANNALS OF ONCOLOGY, 2006, 17 (08) :1185-1196

← 1 2 3 4 5 →